Goldman Sachs Group Inc Cullinan Oncology, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 700,552 shares of CGEM stock, worth $9.42 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700,552
Previous 452,787
54.72%
Holding current value
$9.42 Million
Previous $7.9 Million
48.52%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CGEM
# of Institutions
146Shares Held
67.6MCall Options Held
612KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$103 Million19.97% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$77.3 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$47.8 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$45.9 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$44.1 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $613M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...